Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Exelixis
Information provided by (Responsible Party):
Goyal, Lipika, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01954745
First received: September 24, 2013
Last updated: September 15, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2015
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)